Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Health Policy Department, Harvard University, Cambridge, Massachusetts, USA.
J Womens Health (Larchmt). 2020 Aug;29(8):1113-1121. doi: 10.1089/jwh.2019.8007. Epub 2020 Apr 1.
Medication use among pregnant women is widespread, despite limited evidence about the teratogenicity of most medications. Improved physician-patient communication about pregnancy-related medication safety has been identified as a strategy to address this critical issue; however, little is known about physicians' knowledge, attitudes, and practices that could inform tools for information access and sharing to support such communication. The primary objective of this study is to address gaps in what is known about obstetrician-gynecologist views, practices, and needs related to accessing and sharing pregnancy-related medication safety information with patients. The basis for this study is a nationally representative, randomized survey of 506 practicing obstetrician-gynecologists. The survey was completed by mail or online between October 26, 2015 and May 8, 2016 with a 52% response rate. Data were weighted to population parameters to reduce the risk of potential nonresponse biases. Analyses included univariate distributions and comparisons between physicians in different residency cohorts using all-pairs dependent -tests. Findings point to critical features of obstetrician-gynecologist access and sharing of medication safety information. Obstetrician-gynecologists often retrieve medication safety information during a clinical visit. There is widespread provision of potentially problematic "safe lists" to patients, particularly by younger cohorts, and limited counseling for reproductive-aged patients not actively planning a pregnancy. To improve clinical care, physician-patient communication may be enhanced with technical and policy solutions, including improved digital information tools for retrieving and discussing information in the clinical setting; evidence-based, written information for physicians to share with patients; and encouragement for counseling all women of reproductive age receiving teratogenic medications.
孕妇用药较为普遍,尽管大多数药物的致畸性证据有限。提高医患之间关于妊娠相关药物安全性的沟通被认为是解决这一关键问题的策略;然而,对于医生的知识、态度和实践,我们知之甚少,这些因素可能会影响到信息获取和共享工具的开发,以支持这种沟通。本研究的主要目的是填补我们对于妇产科医生在获取和共享与患者相关的妊娠药物安全信息方面的看法、实践和需求的认识空白。本研究的依据是一项对 506 名执业妇产科医生进行的全国代表性、随机调查。调查于 2015 年 10 月 26 日至 2016 年 5 月 8 日通过邮件或在线完成,回复率为 52%。数据经过加权处理,以符合人口参数,降低潜在非应答偏差的风险。分析包括使用所有对依赖检验比较不同住院医生群体的单变量分布和差异。研究结果指出了妇产科医生获取和共享药物安全信息的关键特征。妇产科医生通常在临床就诊期间检索药物安全信息。广泛向患者提供潜在有问题的“安全清单”,尤其是年轻医生,而对于未积极计划怀孕的育龄患者,提供的咨询则有限。为了改善临床护理,医患沟通可以通过技术和政策解决方案得到加强,包括改善在临床环境中检索和讨论信息的数字信息工具;为医生与患者分享的循证书面信息;鼓励向所有接受致畸药物的育龄妇女提供咨询。